Pathos AI raises $237M for cancer drug development
SiliconANGLE: AI drug development startup Pathos AI closes $237M investment
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic. Pathos is developing cancer drugs […] The post AI drug development startup Pathos AI closes $237M investment appeared first on SiliconANGLE.
Get smart on it
Pathos AI, a startup developing cancer drugs using an artificial intelligence platform called Foundry, raised $237 million in funding at a $3 billion valuation, with pharmaceutical giant Bristol Myers Squibb leading the investment round. Foundry analyzes approximately 200 petabytes of oncological data to help researchers identify the most promising drug candidates and the patients most likely to benefit from them, while also planning clinical trials based on biomarkers. The funding will support Pathos' drug development programs, including efforts to develop cancer therapies such as antibody-drug conjugates and ER PROTAC drugs, as well as a collaboration with Bristol Myers Squibb and Tempus AI involving the licensing of anonymized patient data on neurological conditions. The partnership demonstrates how pharmaceutical companies are integrating artificial intelligence platforms into drug discovery and clinical trial processes to improve the probability of success in drug development.
Relevant courses
Want to go deeper than the news? Explore live, cohort-based AI courses taught by practitioners.
Browse AI courses on MavenRelated news
OpenAI working on new $30B raise at $1.25T valuation ahead of IPO
Should OpenAI command an over $1 trillion valuation with this round, it would break records as the most highly valued private company ever.
Also reported by SiliconANGLE
OpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
Also reported by TechCrunch, SiliconANGLE and The Decoder
DeepSeek reportedly raises $15B days after US restrictions
DeepSeek has reportedly raised $15 billion in one of China's largest funding rounds, just days after the US ordered federal agencies to remove its technology over national security concerns.
Otter.ai raises $320M in funding for its AI meeting assistant
Otter.ai Inc., the developer of a popular artificial intelligence meeting assistant, today announced that it has raised $320 million in funding. The capital came entirely from General Catalyst’s Customer Value Fund. The investment vehicle provides startups with financing for sales and marketing initiatives. General Catalyst doesn’t take a stake in portfolio companies, but instead receives […] The post Otter.ai raises $320M in funding for its AI meeting assistant appeared first on SiliconAN
Meta to create a new class of shares to fund AI push
Meta says it's issuing a new class of shares to fund its AI initiatives. As part of its third-quarter earnings report released on Wednesday, the company says the non-voting stock will also go toward potential acquisitions and employee compensation, with trading beginning in 2027. "The scale of investment required to compete, sustain growth, expand infrastructure, and pursue new strategic initiatives amidst the AI transformation taking place in the industry is significant," Meta
Also reported by TechCrunch
Year-old AI research lab Flapping Airplanes raises $1B at a reported $6B valuation
Artificial intelligence research lab Flapping Airplanes Inc. today announced it has raised $1 billion in new funding, about a year after it was founded. Investors valued the startup at $6 billion in the deal, Bloomberg reported. No commercial product has come out of the lab yet. Flapping Airplanes is trying to build AI models that […] The post Year-old AI research lab Flapping Airplanes raises $1B at a reported $6B valuation appeared first on SiliconANGLE.